muscle function News
-
Chemical widely used in antibacterial hand soaps may impair muscle function
Triclosan, an antibacterial chemical widely used in hand soaps and other personal-care products, hinders muscle contractions at a cellular level, slows swimming in fish and reduces muscular strength in mice, according to researchers at the University of California, Davis, and the University of Colorado. The findings appear online in the Proceedings of the National Academy of Sciences of the ...
-
Signifier Medical Receives Prestigious 2020 GOOD DESIGN Award for Superior Design Excellence
Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA®, the first and only daytime intraoral neuromuscular stimulation device for treating mild obstructive sleep apnea and snoring, has received the prestigious GOOD DESIGN® Award in the Medical category. The device was recently approved by the U.S. Food and Drug Administration ...
-
NRDC lawsuit forces FDA to take action on dangerous chemical in soaps
The U.S. Food and Drug Administration, under a court agreement signed yesterday, will end decades of delay and decide how to protect consumers from triclosan, a suspected endocrine disruptor linked to reproductive and developmental harm in laboratory studies. FDA first proposed in 1978 to remove triclosan from certain consumer products. But because it took no further action, the chemical has ...
-
eXciteOSA® Daytime Sleep Apnea Therapy Device Surpasses 50,000 Patient Session Milestone
Signifier Medical Technologies Ltd, an innovator in the sleep-disordered breathing market, announced today that it has hit the 50,000 therapy session milestone with its innovative eXciteOSA® sleep device. Following FDA authorization and clearance for marketing in February 2021, eXciteOSA has been quickly adopted by physicians and patients alike. The first of its kind, eXciteOSA is a daytime ...
-
Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. New real-world data will be presented evaluating SOLIRIS® (eculizumab) for the treatment of generalized myasthenia gravis (gMG) in the United ...
-
Signifier® Medical Ushers In New Era of Treatment for Sleep Apnea and Snoring with FDA Approval of eXciteOSA® Device
The FDA has approved eXciteOSA, the revolutionary first-ever daytime treatment for mild obstructive sleep apnea and snoring. Used for only 20 minutes per day for a period of six weeks and then twice per week, the therapy is clinically proven to improve the quality of sleep by significantly reducing obstructive sleep apnea and snoring. Signifier Medical Technologies, an innovator in the sleep ...
-
NRDC: Dangerous Chemical in Soaps and Toothpaste Facing Closer Scrutiny
Acting under pressure from a Natural Resources Defense Council lawsuit, the U.S Food and Drug Administration today proposed a federal rule that, if finalized, would remove the potentially hazardous chemical triclosan from consumer body washes and hand soaps. “This is a good first step toward getting unsafe triclosan off the market,” said Mae Wu, an attorney in NRDC’s health ...
-
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States Upfront Payment of $30 Million Received in 1 st Quarter Strengthens Cash Position and Extends Cash Runway Positive Phase 2 Results Published in The Lancet Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy Pivotal Phase 3 Trial ...
-
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 17, 2021 at 4:25 p.m. (11:25 a.m. ET). The presentation will be webcast live and ...
-
Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission
Case Western Reserve University, in collaboration with NDI Medical LLC, SPR™ Therapeutics, and Valtronic, has been awarded a $3 million grant from the Ohio Third Frontier Commission to commercialize a neurostimulation technology platform designed to treat multiple clinical indications with significant unmet needs, including pain and muscle paralysis. The Ohio Third Frontier Innovation ...
-
Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum. The presentation is scheduled for Thursday, November 18, 2021 at 10:00 a.m. ET. The ...
-
Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2021 financial results on Tuesday, February 22, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. ...
-
The Lancet Publishes Positive Results from Capricor Therapeutics` Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention ...
-
Axogen to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in two investor conferences in February. Karen Zaderej, chairman, CEO, and president will participate in a fireside discussion at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on ...
-
The Lancet: Nerve transfer surgery restores hand function and elbow extension in 13 young adults with complete paralysis
Nerve transfer surgery has enabled 13 young adults with complete paralysis to regain movement and function in their elbows and hands, according to the largest case series of this technique in people with tetraplegia (paralysis of both the upper and lower limbs), published in The Lancet. During the surgery, Australian surgeons attached functioning nerves above the spinal injury to paralysed ...
By Siemens AG
-
CardioWise Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Receives Patents from Both the United States and the European Union
CardioWise, Inc., is pleased to announce two significant patents protecting its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). The European Union Patent Number 12839978.9 was awarded on February 2, 2019, followed closely by the U.S. Patent on June 7, 2019 (patent application number 14/350,991). Both patents are entitled “Methods for Evaluating ...
-
Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has been selected to ride on the 2022 Donate Life Rose Parade Float. Additionally, organ and tissue donor Paul Flanders will be honored through a floragraph that will adorn the ...
-
Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2022 meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN), and the American Society for Reconstructive Microsurgery (ASRM). The meetings will be ...
-
Neurolutions IpsiHand Stroke Rehabilitation Device Authorized by FDA
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion. The Neurolutions IpsiHand Upper Extremity Rehabilitation System (IpsiHand System) is a Brain-Computer-Interface (BCI) device that assists in rehabilitation ...
By Neurolutions
-
FDA Awards Breakthrough Device Designation to the ReWalk ReBoot Soft Exo-Suit
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading global manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced its ReBoot device has been granted designation as a Breakthrough Device by the Food and Drug Administration (FDA). The ReBoot is a lightweight, battery-powered orthotic exo-suit intended to assist ambulatory ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you